Articles from IGI, Inc.

Ichnos Glenmark Innovation (IGI) Announces Appointment of Mariana Cota Stirner, M.D., Ph.D., as Chief Medical Officer

Physician-Scientist with Proven Track Record of Global Drug Development and Regulatory Approvals to Lead Clinical Development of IGI’s Multispecific™ Oncology Pipeline

By IGI, Inc. · Via GlobeNewswire · June 23, 2026

Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors

Next-generation multispecific antibody, ISB 2301, targets 3 tumor-associated antigens (TAAs) and activates both T cells and natural killer (NK) cells

By IGI, Inc. · Via GlobeNewswire · May 20, 2026

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

NEW YORK and NORTH CHICAGO, Ill., July 10, 2025 (GLOBE NEWSWIRE) -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT® protein platform, for oncology and autoimmune diseases.

By IGI, Inc. · Via GlobeNewswire · July 10, 2025

Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma

TRIgnite-1 study shows an overall response rate (ORR) of 74% across nine dose levels, in heavily pretreated patients with a median of six prior lines of therapy

By IGI, Inc. · Via GlobeNewswire · June 2, 2025

Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma

Results from the dose-escalation portion of the Phase 1 clinical study of ISB 2001 in patients with heavily pretreated multiple myeloma to be presented at the 2025 ASCO Annual Meeting

By IGI, Inc. · Via GlobeNewswire · May 5, 2025